|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Diazoxide#Drug Interactions]] |
| {{Diazoxide}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Drug Interactions==
| |
| | |
| ===Effects of other drugs===
| |
| | |
| Ticagrelor is predominantly metabolized by CYP3A4 and to a lesser extent by CYP3A5. Ticagrelor is also a p-glycoprotein (P-gp) substrate.
| |
| | |
| ===7.1 CYP3A inhibitors===
| |
| | |
| Avoid use of strong inhibitors of CYP3A (e.g., [[ketoconazole]], [[itraconazole]], [[voriconazole]], [[clarithromycin]], [[nefazodone]], [[ritonavir]], [[saquinavir]], [[nelfinavir]], [[indinavir]], [[atazanavir]] and [[telithromycin]]) [see Warnings and Precautions (5.6) and Clinical Pharmacology (12.3)].
| |
| | |
| ===7.2 CYP3A inducers===
| |
| | |
| Avoid use with potent inducers of CYP3A (e.g., [[rifampin]], [[dexamethasone]], [[phenytoin]], [[carbamazepine]] and [[phenobarbital]]) [see Warnings and Precautions (5.7) and Clinical Pharmacology (12.3)].
| |
| | |
| ===7.3 Aspirin===
| |
| | |
| Use of BRILINTA with [[aspirin]] maintenance doses above 100 mg reduced the effectiveness of BRILINTA [see Warnings and Precautions (5.2) and Clinical Studies(14)].
| |
| | |
| Effect of BRILINTA on other drugs
| |
| | |
| Ticagrelor is an inhibitor of CYP3A4/5 and the P-glycoprotein transporter.
| |
| | |
| ===7.4 Simvastatin, lovastatin===
| |
| | |
| BRILINTA will result in higher serum concentrations of [[simvastatin]] and [[lovastatin]] because these drugs are metabolized by CYP3A4. Avoid simvastatin and [[lovastatin]] doses greater than 40 mg [see Clinical Pharmacology (12.3)].
| |
| | |
| ===7.5 Digoxin===
| |
| | |
| [[Digoxin]]: Because of inhibition of the P-glycoprotein transporter, monitor digoxin levels with initiation of or any change in BRILINTA therapy [see Clinical Pharmacology(12.3)].
| |
| | |
| ===7.6 Other Concomitant Therapy===
| |
| | |
| BRILINTA can be administered with unfractionated or low-molecular-weight heparin, GPIIb/IIIa inhibitors, proton pump inhibitors, [[beta-blockers]], [[angiotensin converting enzyme inhibitors]], and [[angiotensin receptor blockers]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PROGLYCEM (DIAZOXIDE) SUSPENSION [TEVA GLOBAL RESPIRATORY RESEARCH LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b16c7832-2fd9-49af-b923-1dc0d91fd6e2 | publisher = | date = | accessdate = 26 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{reflist|2}}
| |
| | |
| {{Nonsympatholytic vasodilatory antihypertensives}}
| |
| {{Other therapeutic products}}
| |
| {{Channel openers}}
| |
| | |
| [[Category:Sulfonamides]]
| |
| [[Category:Vasodilators]]
| |
| [[Category:Potassium channel openers]]
| |
| [[Category:Benzothiadiazines]]
| |
| [[Category:Organochlorides]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |